Eisai Co. Ltd.

In News

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan | News Release：2025 | Eisai Co., Ltd. - Eisai

Eisai - Jun 02, 2025

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - Biogen

Biogen - Nov 28, 2025

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year - TradingView — Track All Markets

TradingView — Track All Markets - Dec 16, 2025

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PR Newswire

PR Newswire - Dec 03, 2025

Why Eisai Co. Ltd. (EII) stock signals breakout potential - Global Markets & Weekly High Return Stock Forecasts - ulpravda.ru

ulpravda.ru - Dec 20, 2025

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China - Eisai

Eisai - Aug 18, 2025

Clinical Pharmacology Update: Leqembi Iqlik From Eisai - Pharmacy Times

Pharmacy Times - Oct 24, 2025

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Biogen

Biogen - Nov 25, 2025

Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting - PR Newswire

PR Newswire - May 22, 2025

History of Enhancing the Company's Corporate Governance - Eisai

Eisai - May 16, 2025

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC - Eisai

Eisai - Jul 31, 2025

Prevention of Environmental Pollution - Eisai

Eisai - Feb 14, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment